Newborn Screening LC-MS Reagent Kits Market Size, Share & Trends Analysis Report By Type (Derivatized, Non derivatized), By Applications (Protein Metabolism, Fatty Acid Metabolism, Organic Acid Metabolism, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Newborn Screening Lc-Ms Reagent Kits Market Size

The global newborn screening lc-ms reagent kits market size was valued at USD 347.18 million in 2025 and is projected to grow from USD 370.86 million in 2026 to USD 628.68 million by 2034, registering a CAGR of 6.82% during the forecast period from 2026 to 2034. North America dominated the newborn screening lc-ms reagent kits market with a market share of 41.5% in 2025.

In recent years, there has been a rise in cases of newborn metabolic disorders like PKU and MSUD, which is estimated to boost the demand for more screenings, thereby driving the global newborn screening LC-MS reagent kits market growth. The rising awareness and education amongst healthcare professionals and parents about newborn screening to diagnose several diseases is expected to augment the market growth. Moreover, technological advancements in the LC-MS technology are estimated to create opportunities for market expansion.

Newborn Screening LC-MS (Liquid Chromatography-Mass Spectrometry) Reagent Kits are diagnostic tools used in newborn screening programs to detect inherited metabolic disorders (IMDs) early in a baby's life. These disorders, such as phenylketonuria (PKU) or maple syrup urine disease (MSUD), can lead to severe health complications if left untreated.

The kits contain specialized reagents optimized for LC-MS analysis, enabling the identification and quantification of specific metabolites in blood or urine samples. LC-MS provides high sensitivity and specificity, allowing for accurate detection of IMDs.

Early detection through newborn screening allows for timely intervention, such as dietary modification or medical treatment, which can prevent or minimize the development of symptoms and improve long-term health outcomes. These reagent kits play a crucial role in public health initiatives aimed at ensuring the early diagnosis and management of IMDs in newborns.

Type Insights

The non-derivatized method is more rapid and cost-effective and needs minimum preventive maintenance than the derivatized method. It is frequently used in the initial stage of newborn screening, and derivatized reagent kits are used only to confirm the test. Therefore, the consumption of non-derivatized reagents is higher than that of derivatized reagents. In line with this, several key market players are launching new non-derivatized MSMS kits.

• For instance, in January 2018, Perkin Elmer announced the launch of its NeoBase 2 non-derivatized MSMS kit for the semi-quantitative measurement and evaluation of amino acid, succinyl acetone, free carnitine, acylcarnitine, nucleoside and Lys phospholipid concentrations.

The kit evaluates newborn heel prick blood samples dried on filter paper and is used with a tandem mass spectrometer. Such factors boost the segment growth.

Request Customizationto receive a tailored report.

Application Insights

The protein acid metabolism segment dominates the global market. LC-MS (Liquid Chromatography-Mass Spectrometry) reagent kits are utilized to analyze protein acid metabolism. These kits contain specialized reagents and solutions for preparing, separating, and detecting proteins and their metabolites using LC-MS techniques. In the context of protein acid metabolism, LC-MS reagent kits enable the identification and quantification of various protein metabolites generated through metabolic processes involving amino acids.

By employing these kits, researchers can effectively study the dynamics of protein turnover, post-translational modifications, and metabolic pathways. LC-MS offers high sensitivity and specificity, allowing for detecting low-abundance metabolites and subtle changes in protein metabolism. Thus, LC-MS reagent kits facilitate comprehensive investigations into protein acid metabolism, contributing to advancements in understanding cellular processes, disease mechanisms, and drug development.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant market shareholder and is expected to expand substantially during the forecast period. North America is leading the global newborn screening LC-MS market, owing to the well-developed newborn screening program being followed across all the U.S. states. In the US, every infant is screened; roughly 4 million babies are examined each year. The U.S. Health Department has released free information to help parents manage these illnesses in an effort to raise awareness about newborn screening.

• For instance, in December 2014, members of Congress in the U.S. passed the Newborn Screening Saves Lives Reauthorization Act bill to renew and upgrade federal initiatives for newborn screening.

In the U.S., state governments have upgraded child healthcare through newborn screening programs.

• For instance, the Research Triangle Institute (RTI), in alliance with the CDC and National Center on Birth Defects and Developmental Disabilities, is conducting research studies and programs to advance awareness about newborn screening policy practices.

These prompt initiatives are adding fuel to the market growth. PerkinElmer and Tech. Dev. Pte are some of the key players in the U.S., further contributing to regional market growth.

Moreover, there has been a rise in metabolic disorders in newborns in the North American region.

• For instance, as per the National Organization for Rare Diseases (NORD), the estimated incidence of PKU in newborn screening programs varies between one in 13,500 to 19,000 newborns in the United States. Consequently, all these factors are estimated to augment North America's newborn screening LC-MS reagent kits market.

Unlock Regional Insightsto access country-level data, & regional trends.

Middle East and Africa Newborn Screening Lc-Ms Reagent Kits Market Trends

The Middle East and Africa market is projected to grow at a moderate CAGR during the forecast period. The population in the region is around 400 million, with a high birth rate, and is assessed to 10 million newborns annually. In line with this, the region offers favorable growth opportunities for the product. However, socio-economic barriers are hampering the adoption of newborn screening tests.

In recent decades, countries like Saudi Arabia, Qatar, and Lebanon have become regional and international pioneers for newborn screening applications through tandem mass spectrometry. National NBS programs with extensive screening coverage are now in Bahrain, Egypt, Iran, Israel, Kuwait, Oman, Qatar, the State of Palestine, Saudi Arabia, and the United Arab Emirates. Moreover, surging efforts by the government to spread awareness regarding newborn screening procedures will upsurge its adoption to some extent. This is estimated to boost the region's newborn screening LC-MS reagent kits industry.

List of Key and Emerging Players in Newborn Screening LC-MS Reagent Kits Market